1 |
Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599-609.
DOI
|
2 |
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808.
DOI
|
3 |
U.S. Food and Drug Administration. FDA approves Botox to treat chronic migraine. Available from: https://wayback.archive-it.org/7993/20170112032340/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ ucm229782.htm (updated 2017 Feb 1).
|
4 |
Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985;12:314-6.
DOI
|
5 |
Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013;306:124-46.
DOI
|
6 |
Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011;51:1573-7.
DOI
|
7 |
Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993;113:400-4.
DOI
|
8 |
Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi 2001;105:218-22.
|
9 |
Rosales RL, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996;19:488-96.
DOI
|
10 |
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93.
DOI
|
11 |
Filipovic B, Matak I, Bach-Rojecky L, Lackovi Z. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PloS One 2012;7:e29803.
DOI
|
12 |
Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011;186:201-7.
DOI
|
13 |
Baumel JJ, Vanderheiden JP, McElenney JE. The auriculotemporal nerve of man. Am J Anat 1971; 130:431-40.
DOI
|
14 |
Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010;50:1406-18.
DOI
|
15 |
Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the treatment of headache. Headache 2013;53 Suppl 2:54-61.
DOI
|